Use of advanced treatment technologies among men at low risk of dying from prostate cancer. - Wikidata - wikimedia - TriplyDB

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

http://www.wikidata.org/entity/Q37378693

about

Penile rehabilitation after radical prostatectomy: does it work?Current clinical challenges in prostate cancer Screening and detection advances in magnetic resonance image-guided prostate biopsy Secondary data analysis of large data sets in urology: successes and errors to avoid.The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base Direct Administration of Nerve-Specific Contrast to Improve Nerve Sparing Radical Prostatectomy.Rapid expansion of new oncology care delivery payment models: results from a payer survey.Reimbursement and use of intensity-modulated radiation therapy for prostate cancer.Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care.American trends in expectant management utilization for prostate cancer from 2000 to 2009.Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population.Treatment of localized prostate cancer in elderly patients.The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.The Effect of the Diffusion of the Surgical Robot on the Hospital-level Utilization of Partial Nephrectomy Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer.Implications of evolving delivery system reforms for prostate cancer care.The impact of technology diffusion on treatment for prostate cancer.Expectant management of veterans with early-stage prostate cancer.Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant)Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population Impact of urologists' ownership of radiation equipment in the treatment of prostate cancer.High tech or high risk? An analysis of media reports about robotic surgery.Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.Probability modeling of the number of positive cores in a prostate cancer biopsy session, with applications.A survey of patient expectations regarding sexual function following radical prostatectomy.Accuracy of dose planning for prostate radiotherapy in the presence of metallic implants evaluated by electron spin resonance dosimetry Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.Managing localized prostate cancer in the era of prostate-specific antigen screening.Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study.Decision-making processes among men with low-risk prostate cancer: A survey study.Variation in the use of active surveillance for low-risk prostate cancer.Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology.Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer.Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer.How can we optimize the use of prostate cancer registries?Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.Robotic surgery in urological oncology: patient care or market share?

P2860

Q26773762-FB644E00-6BB5-429A-97F4-DD03C8EFA248 Q26866036-2621A2C0-BF8D-4E3D-BF01-DA3888ED3F81 Q26991785-0A6AB57E-EC38-4E99-B65A-BC4CB8451309 Q30680391-A5A62C50-9058-456B-941A-EA57AA394B17 Q30802068-3F9BE022-2027-44A7-A9D6-8663297D7E6D Q30840012-CFD882C4-9DB6-419C-A65E-9C838C25BFD9 Q33652837-247238E0-AC4E-483D-914F-63D6B817C26A Q33833551-72DF3989-1073-43E6-85E4-81913757DAC5 Q33905899-54DEA3D0-FAAB-4D21-AF73-BA803DE7BCD7 Q34031640-0FAB5681-5097-468E-8831-767939F12154 Q34602118-8436E8FB-2C25-49DF-A536-A41288497FF7 Q35151890-6B05F741-908E-4ADD-9ADC-7CF37FB89734 Q35912658-8F45C888-3365-49AF-B543-165CFEC15EA2 Q36259082-2AE4F189-8EDE-4474-843C-E4197AEC9D72 Q36450058-252CE41F-3C78-4EE0-AC69-6FE8C6086F8A Q36668945-5CE70255-CF5D-406D-8A4A-06D4DFB81522 Q37426228-C22E2A4A-EA72-449F-84EE-B8BAA35F0284 Q37564852-4C7A427E-446E-4CD4-967B-18442EEBDD07 Q38626027-8D7DB6CD-E4CF-4CF1-8E40-5279B4C99DD6 Q38781628-2A8F4F64-ABD1-441A-AF30-C054F25CB4B5 Q38804659-1D6FE37F-1ACF-422D-A6C4-42CB7217985C Q38845149-7C16419A-171E-4670-97E3-B25464B8FEFA Q38871505-64E7291C-087E-4168-BDB7-12B8CA3E3B07 Q39252098-6F83BD15-A0EB-42B9-9D4D-02D87E5E8A87 Q40077368-669FE6E1-E3CE-4F1E-8F79-A5861011CA3D Q40289101-F542FEF7-D462-47A0-A664-1B784E9E9E14 Q40576790-88283A9B-0A16-4408-862A-6BE2E55CE176 Q41634643-C56FC3FB-DA17-4CBA-86A7-246490D63D82 Q42097767-D0BC2EB5-55E9-4331-B32D-8DF25F5968CA Q42265374-AEA230A7-B778-4DE9-8906-845CED5B5525 Q42770558-BEA69AF7-F1CB-40C5-AABE-E50F0DE1EE81 Q44004278-62F7A69C-1419-4B63-8970-02762A7C6BBB Q46259067-6CC1BF2B-2F75-4B52-AB0D-823CC7CA5710 Q47809867-A16A9BA5-72D9-4CEA-8232-4A72B7A1CFF0 Q47992784-FB94A6EA-09F2-42D7-8EA3-BD90B1BAEA87 Q48085035-B797EE01-1D15-4CF9-807E-E7EC35BC2A57 Q48141226-7984AE73-A75D-4C7F-ACBB-2C34EDF83147 Q48196067-A7F04C59-96B6-4A5B-AE6F-6BEEAAAC3D1E Q48321700-7B204010-89DB-4ADC-BF13-967EA9D05140 Q48657489-D58C7E79-46A2-4A76-9144-AC4BC9971246

P2860

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

http://www.wikidata.org/entity/Q37378693

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Use of advanced treatment tech ...... of dying from prostate cancer.

@en

Use of advanced treatment tech ...... of dying from prostate cancer.

@nl

type

label

Use of advanced treatment tech ...... of dying from prostate cancer.

@en

Use of advanced treatment tech ...... of dying from prostate cancer.

@nl

prefLabel

Use of advanced treatment tech ...... of dying from prostate cancer.

@en

Use of advanced treatment tech ...... of dying from prostate cancer.

@nl

P1433

Q37378693-2146D8B5-77CC-4648-8AFE-AAB5BB10EAF9

P1476

Q37378693-8C80A62B-BCD6-4FE4-B95A-649314B66225

P2093

Q37378693-091428CB-BBA6-4273-AB97-4A35191C3DC3

Q37378693-1F60195F-141C-4316-BB8C-CDE312E5A07A

Q37378693-3D90CF80-FB95-43BF-AC29-CD854A040324

Q37378693-3DA5562B-CE98-4BE5-9E93-6E670E85DF9B

Q37378693-5C7CBC21-26B0-4F09-A115-F292CF2C675E

Q37378693-651510F9-B3F2-498A-825D-6F025448F5F2

Q37378693-8B960A98-8F8C-4382-A7DD-183ED9DE2663

Q37378693-8C1DC960-676C-44C6-9FE9-8E338317645C

Q37378693-CDBBC18A-8D1A-4DE7-B682-98FF629C773F

P2860

Q37378693-0234ED50-CC55-4BFF-A63E-04714642DAC9

Q37378693-0BA90570-2C7F-4D98-AA98-42242B34D6E5

Q37378693-18ADD181-AD63-431B-8D1A-E7C96926EFE1

Q37378693-1F26BB22-ACBA-449F-8C34-AA3E7F935823

Q37378693-20B358B8-1AB4-4E1B-8673-93EF9D277CA8

Q37378693-27680947-CAF0-4B8C-9FCD-811B20CF2C2E

Q37378693-37AB5586-7AB3-4FCA-933B-48A102448240

Q37378693-37BB7017-9BEF-4E18-9E7E-6A31C92C9C3B

Q37378693-3D6B5CD5-CC56-4DE3-83D8-F9CDD0BD7019

Q37378693-5A77F890-261D-45F3-9B86-239DFD39734F

P304

Q37378693-ACA8BDE9-F850-4FD0-BCFA-A43D7BBB5438

P31

Q37378693-59152112-6533-4A4C-9AE5-9CCC422600D4

P356

Q37378693-3D4C054C-4F8A-4F84-9F5C-7FD59A7A2D8C

P407

Q37378693-FA34CD94-7BFE-4003-BA45-F3E226A04683

P433

Q37378693-C7205853-32BA-4D98-8CBE-8F1613EA521A

P478

Q37378693-1F038C31-8D00-496D-83AC-B00FBAAB42F5

P50

Q37378693-295A8FC0-EBAF-4208-823A-D3B79253E937

Q37378693-F75E032D-207F-405C-9A44-4F468816331C

P577

Q37378693-2E2B264D-1F43-4967-B49C-3364012E6094

P698

Q37378693-2699FFF5-EE15-43DF-9128-3D0BFA124DFA

P932

Q37378693-0846B7AE-0094-4D7B-8716-072CD4313FAC

P356

P1433

Journal of the American Medical Association

P1476

Use of advanced treatment tech ...... of dying from prostate cancer

@en

P2093

Brent K Hollenbeck

http://www.w3.org/2001/XMLSchema#string

Bruce L Jacobs

http://www.w3.org/2001/XMLSchema#string

David C Miller

http://www.w3.org/2001/XMLSchema#string

James E Montie

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Rodney L Dunn

http://www.w3.org/2001/XMLSchema#string

Scott M Gilbert

http://www.w3.org/2001/XMLSchema#string

Ted A Skolarus

http://www.w3.org/2001/XMLSchema#string

Yun Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Outcomes of localized prostate cancer following conservative management

Cancer statistics, 2010

Screening and prostate-cancer mortality in a randomized European study

Development of a comorbidity index using physician claims data.

Comparative effectiveness of external-beam radiation approaches for prostate cancer.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

NCCN clinical practice guidelines in oncology: prostate cancer.

Comorbidities, treatment and ensuing survival in men with prostate cancer

Value-based insurance design: more health at any price.

20-year outcomes following conservative management of clinically localized prostate cancer.

P304

2587-2595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.6882

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

309

http://www.w3.org/2001/XMLSchema#string

P50

Florian R. Schroeck

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23800935

http://www.w3.org/2001/XMLSchema#string

P932

3857348

http://www.w3.org/2001/XMLSchema#string